Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02210702
Other study ID # 14-06-FB-0118-HOSP
Secondary ID
Status Recruiting
Phase Phase 4
First received July 31, 2014
Last updated August 4, 2014
Start date July 2014

Study information

Verified date August 2014
Source The Jones Institute
Contact Kelly McDaniel, MS
Email mcdanik@evms.edu
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, controlled cohort study. This study will look at the effect of Ethinyl Estradiol 35mcg/Norethindrone 1mg and Ethinyl Estradiol 20 mcg/Norethindrone 1mg on postpartum depressive symptoms and sexual function scores when compared to a control group using no hormonal contraception. Depressive symptoms and sexual function will be measured using the Edinburgh Postnatal Depression Scale (EPDS), Arizona Sexual Experiences Scale (ASEX), and Brief Index of Sexual Functioning for Women (BISF-W). Participants will begin taking the medication at Week 3 postpartum, and these outcomes will be measured at baseline (0-1 day postpartum), Week 3, and Week 6-7. The investigators hypothesize that there will be an ethinyl estradiol dose related response in EPDS, ASEX, and BISF-W scores at Week 6-7, which would indicate a decrease in depressive symptoms and increase in sexual function in both of the oral contraceptive groups.


Recruitment information / eligibility

Status Recruiting
Enrollment 33
Est. completion date
Est. primary completion date January 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- 18-45 year old women who desire contraception postpartum for at least 6 weeks.

- 18-45 year old women who choose not to use oral contraceptive medication postpartum for at least 6 weeks for the control group.

Exclusion Criteria (Medication groups):

- Breastfeeding (although this may limit participant enrollment, combined oral contraceptives are contraindicated in this population).

- Delivery by cesarean section.

- Previous history of depression, mood disorders, or psychiatric disorders.

- Any condition (history or presence of) which contraindicates the use of combination OCs, including:

- Thrombophlebitis or thromboembolic disorders, known or suspected clotting disorders, deep vein thrombosis, thrombogenic valvulopathies or rhythm disorders.

- Pulmonary Embolism.

- Cerebrovascular or coronary artery disease or myocardial infarction.

- Diabetes mellitus.

- Migraine headaches with focal, neurological symptoms.

- Chronic renal disease.

- Uncontrolled or untreated hypertension.

- Cholestatic jaundice.

- Known or suspected carcinoma of the breast, endometrial carcinoma, or known or suspected estrogen-dependent neoplasia.

- Impaired liver function or disease, hepatic adenomas or carcinomas.

- Known hypersensitivity to estrogens and/or progestins.

- History of thyroid disorders.

- Recent alcohol or drug use.

- Smoking and age =35 or smokers who will become 35 years of age during the study.

- Known history of noncompliance with taking medication.

Exclusion Criteria (Control group):

- Previous history of depression, mood disorders, or psychiatric disorders.

- Recent alcohol or drug use.

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Drug:
Ethinyl Estradiol 35mcg/Norethindrone 1mg

Ethinyl Estradiol 20mcg/Norethindrone 1mg


Locations

Country Name City State
United States Sentara Norfolk General Hospital Norfolk Virginia

Sponsors (1)

Lead Sponsor Collaborator
The Jones Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Edinburgh Postnatal Depression Scale at baseline, 3 weeks postpartum and 6 weeks pospartum Baseline (0-1 days postpartum), Week 3 Postpartum, Week 6-7 Postpartum No
Primary Change in Arizona Sexual Experiences Scale scores at baseline, 3 weeks postpartum, and 6-7 weeks postpartum Baseline (0-1 days postpartum), Week 3 Postpartum, Week 6-7 Postpartum No
Primary Change in Brief Index of Sexual Functioning for Women scores at baseline, week 3 postpartum, and week 6-7 postpartum Baseline (0-1 days postpartum), Week 3 Postpartum, Week 6-7 Postpartum No
Secondary Time to First Coitus Time to first coitus during postpartum period No
Secondary Urine Pregnancy Test Week 6-7 Postpartum No